… responsible for progressive fibrotic diseases and use of the … to improve the drug development
pipeline for pulmonary fibrosis. … high-throughput drug discovery or validation of drug effects. …

… In summary, drug discovery and development in IPF appear to be crowded areas and with
several challenges. The preclinical studies need to be better designed taking into account the …

… In this review, we critically discuss how cutting-edge research in disease pathogenesis may
translate into identification of new therapeutic targets, thus facilitate drug discovery. There is …

… drugs for the treatment of (idiopathic) pulmonary fibrosis have fuelled basic, translational and
clinical research and drug … niche, has become the starting point for precision drug discovery…

… Part A contains flavonoids with anti-pulmonary fibrosis, Part B contains alkaloids, Part C …
with anti-pulmonary fibrosis. Relevant anti pulmonary fibrosis mechanisms involve oxidative …

… and in vivo animal models of fibrosis and in human disease point toward reactive oxygen
species being key players in the establishment and progression of pulmonary fibrosis. There is …

… to be implicated in pulmonary fibrosis. Although the etiology of … show how AECs are involved
in pulmonary fibrosis (Figure 2A). … of emerging therapeutic targets for IPF in drug discovery. …

… of the drug in healthy subjects and pulmonary fibrosis patients [Citation107]. A phase II
randomized, double-blind, placebo controlled to evaluate the efficacy and safety of PRM-151 …

… pulmonary fibrosis in mice. To further determine the theraputic impact of the compounds 42,
44 and 45 on lung fibrosis in vivo, bleomycin (BLM)-induced pulmonary fibrosis … a listed drug …

… TGF-β1 activation plays a pivotal role in fibrosis due to its epithelial restriction in lung tissue
[… led to development of severe pulmonary fibrosis in animal models of fibrosis. A recent study …